Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trihexyphenidyl
Drug ID BADD_D02284
Description Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.[A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.[L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]
Indications and Usage Tihexyphenidyl is indicated as an adjunct in the treatment of parkinsonism, an adjuvant in the treatment of parkinsonism with levodopa, and in the control of extrapyramidal disorders caused by central nervous system drugs.[L31773,L31778]
Marketing Status approved
ATC Code N04AA01
DrugBank ID DB00376
KEGG ID D08638
MeSH ID D014282
PubChem ID 5572
TTD Drug ID D09GFL
NDC Product Code 63850-6535
UNII 6RC5V8B7PO
Synonyms Trihexyphenidyl | Benzhexol | Artane | Cyclodol | Hipokinon | Trihexyphenidyl Hydrochloride Elixir | Parkopan | Trihexane | Trihexidyl Hydrochloride | Trihexyphenidyl Hydrochloride | Apo-Trihex | Apo Trihex | ApoTrihex | Parkinane
Chemical Information
Molecular Formula C20H31NO
CAS Registry Number 144-11-6
SMILES C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Accommodation disorder06.02.04.001---
Agitation17.02.05.012; 19.06.02.001--
Angle closure glaucoma06.03.01.001---
Anxiety19.06.02.002--
Asthenia08.01.01.001---
Blindness06.02.10.003; 17.17.01.003---
Chorea17.01.01.001---
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Cycloplegia06.05.03.002; 17.17.02.003---
Delusion19.10.01.001--
Dermatitis23.03.04.002---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysarthria17.02.08.001; 19.19.03.001--
Euphoric mood19.04.02.006--
Feeling abnormal08.01.09.014---
Hallucination19.10.04.003--
Hallucination, visual19.10.04.007---
Headache17.14.01.001--
Hyperkinesia17.01.02.008---
Hypotension24.06.03.002--
Ileus paralytic07.02.05.001---
Intraocular pressure increased13.07.04.002---
Memory impairment17.03.02.003; 19.20.01.003--
Muscle rigidity15.05.04.001; 17.05.02.005---
Mydriasis06.05.03.004; 17.02.11.003---
Nausea07.01.07.001--
Nervousness19.06.02.003---
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene